5-hydroxytryptophan in treatment of moderate to severe OCD

5-hydroxytryptophan combination therapy with fluoxetine in the treatment of moderate to severe OCD: a double blind randomized trial with placebo control

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N106

Enrollment

Registered

2018-04-05

Start date

2018-04-19

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Fluoxetine 60 mg/day+ 5-hydroxytryptophan 100 mg BID for 12 weeks as intervention group. Intervention 2: Control group: Fluoxetine 60mg per day + placebo for 12 wee

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18-60 years old Diagnosis of OCD based on DSM-5 inimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale

Exclusion criteria

Exclusion criteria: Substance dependence IQ less than 70 Any other mental disorder Any serious cardiac, renal or hepatic disease receiving psychotropic medications during the last 6 weeks pregnancy or breast feeding Rising liver transaminases to three times the upper limit of normal or higher

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks: 4, 8, 12 after beginnig of treatment. Method of measurement: Y_BOCS( Yale-Brown obsessive compulsive scale).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026